PIM1 in myeloproliferative neoplasms: potential pathogenic and therapeutic implications. (PubMed, Leukemia) - Sep 29, 2026 - "Although JAK2 inhibitors, such as ruxolitinib, can alleviate constitutional symptoms, they typically fail to eradicate malignant clones or reverse bone marrow fibrosis...PIM kinase inhibitors are currently being evaluated in clinical trials for patients with myelofibrosis. This review summarizes the current understanding of PIM1 biology in the context of MPNs, details the molecular mechanisms underlying its pathogenic contributions, and evaluates the translational potential of PIM1-targeted therapies for MPNs."
Journal • Review • Fibrosis • Hematological Disorders • Hematological Malignancies • Immunology • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • HIF1A • PIM1 • TGFB1
|
|
Avik Dutta; Golam Mohi; Lilian Varricchio; Ronald Hoffman
|